|drug4031||standard treatment Wiki||1.00|
|drug2329||PD-1 blocking antibody+standard treatment Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Sepsis, including viral infections, are major causes of death worldwide. Studies show that in 2017, the number of sepsis patients worldwide reached as high as 48.9 million, of which 11 million patients died. Studies in China also showed that more than 1 million patients died of sepsis in 2015. Previous studies have suggested that sepsis are often secondary to excessive inflammatory response syndrome. However, treatment measures targeting excessive inflammatory response failed to effectively improve the prognosis of patients. PD-1 and PD-L1 are key mediators in T cell depletion in sepsis patients. Therefore, the investigators try to performe a clinical research to investigate the efficacy of PD-1 and thymosin in patients with severe pneumonia associated with lymphocytopenia in 2019 novel coronavirus infection.
Description: proportion of lung injury score decreased 1 or more pointsMeasure: lung injury score Time: 7 days
Description: lymphocyte counts at day 7, 14 and 28 after randimizationMeasure: absolute lymphocyte counts Time: 7, 14 and 28 days
Description: serum level of CRP, PCT and IL-6 at day 3,7 and 14 after randimizationMeasure: serum level of CRP, PCT and IL-6 Time: 3, 7 and 14 days
Description: SOFA score at Day 7, with scores range from 0 to 24 and higher score means worse outcomeMeasure: SOFA score Time: 7 days
Description: died at day 28Measure: all cause mortality rate Time: 28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports